A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization.

Abstract
To estimate how many infants in selected high-risk subgroups would require treatment with respiratory syncytial virus immune globulin (RSV-IG) to avoid 1 hospital admission and to determine whether this is economically justified.